anonymous
Guest
anonymous
Guest
Everything is contingent on the upcoming clinical trial. If it's not as planned then the company will be totally insolvent. No future potential earnings. If it's good it has a change of capturing 2% of the market which still makes this a huge risk. Management hasn't demonstrated any plan other than gutting the employees and sales. ADVISE TO RUN FROM THIS ONE.